Elekta

MEDTECHS DEFLATE FURTHER

13/03/25 -"It has been some time since AlphaValue last bashed MedTechs, its recurring bête noire when it comes to lofty valuations. In fairness the sector has taken care of itself of late. Five years after ..."

PDF page sample
Pages
68
Language
English
Published on
13/03/25
Download
You may also be interested by these reports :
20/10/26
EssilorLuxottica recorded strong growth in Q3 2026, ahead of market expectations, with revenue up 9.0% YoY and 7.2% at constant currency. Management ...
15/10/26
Dräger’s Q3 26 prelims were soft, with sales and EBIT 1.3% and 8.4% below our estimates. EBIT included €20.1m of customs refunds; excluding these, ...
13/10/26
Demant reported robust preliminary Q3 sales figures, driven by strong demand for its newly launched hearing aids. The 2026 guidance has been revised ...
09/10/26
Our target price has been revised downwards due to updated estimates following management’s decision to lower the upper end of its topline guidance ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO